StockNews.AISignal intelligence
Verastem, Inc. · NASDAQ · Healthcare
Browse public VSTM signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Verastem's VS-7375 demonstrates clinical activity with favorable safety in KRAS G12D-mutated pancreatic, lung, and colorectal cancers, per a Boston Business Wire release. While specifics are limited, the results could signal a potential KRAS G12D program catalyst; investors should await fuller data disclosures and timing of upcoming trial updates for a clearer read on value.
View signal analysisVerastem Oncology reported positive updated safety and efficacy from the RAMP 205 RP2D cohort in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). The data show 6-month OS of 86%, PFS 68%, and an ORR of 52% (15/29), with 83% tumor shrinkage at RP2D. If OS data mature and partnerships form, near-term catalysts could boost valuations.
View signal analysisFDA approved Verastem's combination therapy for ovarian cancer patients. This approval may significantly enhance VSTM's market position and revenue.
View signal analysisFDA accepted Verastem's NDA for avutometinib with defactinib. Combination targets recurrent low-grade ovarian cancer with KRAS mutation. NDA received Priority Review; action date is June 30, 2025. Phase 2 trial showed durable response rates in patients. Ongoing trials may expand indications beyond KRAS mutations.
View signal analysisVSTM targets cancer with Avutometinib and Defactinib, pending NDA by 2H2024. Recent stock plunge of 59% may have resulted from safety concerns and equity offering. VSTM has substantial market opportunity; LGSOC potential market estimated at $270 million. Positive early data shows 83% partial response in ongoing trials, indicating robust efficacy. FDA approval could significantly enhance VSTM's valuation and market prospects.
View signal analysis